Evidence map›Paper›PMID 40805246›Full record

ArticleCancers2025

Integration of an OS-Based Machine Learning Score (AS Score) and Immunoscore as Ancillary Tools for Predicting Immunotherapy Response in Sarcomas.

Isidro Machado, Raquel López-Reig, Eduardo Giner, Antonio Fernández-Serra, Celia Requena, Beatriz Llombart, Francisco Giner, Julia Cruz, Victor Traves, Javier Lavernia and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isidro MachadoPathology Department, Instituto Valenciano de Oncología, Calle Gregorio Gea 31, 4to Piso, 46009 Valencia, Spain.ORCID 0000-0001-7318-1330
Raquel López-ReigMolecular Biology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.ORCID 0000-0003-2789-5855
Eduardo GinerPathology Department, Hospital Universitario y Politécnico "La Fe", 46009 Valencia, Spain.
Antonio Fernández-SerraMolecular Biology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.ORCID 0000-0003-0851-5239
Celia RequenaDermatology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Beatriz LlombartDermatology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Francisco GinerPathology Department, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0003-0765-7120
Julia CruzPathology Department, Instituto Valenciano de Oncología, Calle Gregorio Gea 31, 4to Piso, 46009 Valencia, Spain.
Victor TravesPathology Department, Instituto Valenciano de Oncología, Calle Gregorio Gea 31, 4to Piso, 46009 Valencia, Spain.
Javier LaverniaOncology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Antonio Llombart-BoschPathology Department, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0001-9205-103X
José Antonio López GuerreroJoint Cancer Research Unit, IVO-CIPF, 46009 Valencia, Spain.ORCID 0000-0002-7369-8388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

angiosarcomasAS scorecutaneous angiosarcomasImmunoscorenon-cutaneous angiosarcomassarcoma prognosis

Identifiers

PMID40805246
PMCPMC12346403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.